Copyright Reports & Markets. All rights reserved.

Global Antidiabetic SGLT-2 Inhibitor Sales Market Report 2018 by Manufacturer, Region, Type and Application

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Antidiabetic SGLT-2 Inhibitor Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Canagliflozin Market Performance (Volume)
      • 2.1.2 Empagliflozin Market Performance (Volume)
      • 2.1.3 Dapagliflozin Market Performance (Volume)
      • 2.1.4 Other Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Canagliflozin Market Performance (Value)
      • 2.1.2 Empagliflozin Market Performance (Value)
      • 2.1.3 Dapagliflozin Market Performance (Value)
      • 2.1.4 Other Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals Market Performance (Volume)
      • 3.1.2 Clinics Market Performance (Volume)
      • 3.1.3 Other Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Pfizer
      • 4.1.1 Pfizer Profiles
      • 4.1.2 Pfizer Product Information
      • 4.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.2 AstraZeneca
      • 4.2.1 AstraZeneca Profiles
      • 4.2.2 AstraZeneca Product Information
      • 4.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.3 Johnson & Johnson
      • 4.3.1 Johnson & Johnson Profiles
      • 4.3.2 Johnson & Johnson Product Information
      • 4.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.4 GlaxoSmithKline
      • 4.4.1 GlaxoSmithKline Profiles
      • 4.4.2 GlaxoSmithKline Product Information
      • 4.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.5 Merck & Co
      • 4.5.1 Merck & Co Profiles
      • 4.5.2 Merck & Co Product Information
      • 4.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.6 Eli Lilly
      • 4.6.1 Eli Lilly Profiles
      • 4.6.2 Eli Lilly Product Information
      • 4.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.7 Sanofi
      • 4.7.1 Sanofi Profiles
      • 4.7.2 Sanofi Product Information
      • 4.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.8 Takeda Pharmaceuticals
      • 4.8.1 Takeda Pharmaceuticals Profiles
      • 4.8.2 Takeda Pharmaceuticals Product Information
      • 4.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.9 Novo Nordisk
      • 4.9.1 Novo Nordisk Profiles
      • 4.9.2 Novo Nordisk Product Information
      • 4.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.10 Servier Laboratories
      • 4.10.1 Servier Laboratories Profiles
      • 4.10.2 Servier Laboratories Product Information
      • 4.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.11 Boehringer Ingelheim
    • 4.12 Bristol-Myers Squibb

    5 Market Performance for Manufacturers

    • 5.1 Global Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Global Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Global Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 China Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 China Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 China Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 USA Market Performance for Manufacturers
      • 6.2.1 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 USA Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 USA Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 USA Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 Europe Market Performance for Manufacturers
      • 6.3.1 Europe Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 Europe Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 Europe Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Japan Market Performance for Manufacturers
      • 6.4.1 Japan Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Japan Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Japan Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Japan Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 Korea Market Performance for Manufacturers
      • 6.5.1 Korea Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 Korea Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 Korea Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 Korea Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 India Market Performance for Manufacturers
      • 6.6.1 India Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 India Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 India Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 India Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Southeast Asia Market Performance for Manufacturers
      • 6.7.1 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Southeast Asia Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Southeast Asia Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Southeast Asia Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 South America Market Performance for Manufacturers
      • 6.8.1 South America Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 South America Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 South America Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 South America Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Global Antidiabetic SGLT-2 Inhibitor Market Performance (Sales Point)

    • 7.1 Global Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Global Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Global Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) by Regions 2013-2018
    • 7.4 Global Antidiabetic SGLT-2 Inhibitor Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Global Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 China Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 USA Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 Europe Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Japan Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 Korea Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 India Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals Industry
    • 11.2 Clinics Industry
    • 11.3 Other Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Global Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 China Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 USA Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 Europe Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Japan Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Korea Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 India Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 South America Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Canagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Empagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Dapagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Other Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
      • 12.4.4 Other Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Global Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Global Antidiabetic SGLT-2 Inhibitor Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Antidiabetic SGLT-2 Inhibitor for these regions, from 2012 to 2023 (forecast), covering
    China
    USA
    Europe
    Japan
    Korea
    India

    Global Antidiabetic SGLT-2 Inhibitor market competition by top manufacturers/players, with Antidiabetic SGLT-2 Inhibitor sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
    Pfizer
    AstraZeneca
    Johnson & Johnson
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb
    On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Canagliflozin
    Empagliflozin
    Dapagliflozin
    Other
    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Antidiabetic SGLT-2 Inhibitor for each application, including
    Hospitals
    Clinics
    Other

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now